Omega Diagnostics Group PLC VISITECT® CD4 CE-Mark (7714X)

TIDMODX

RNS Number : 7714X

Omega Diagnostics Group PLC

29 November 2017

Omega Diagnostics Group PLC

("Omega" or the "Company")

VISITECT(R) CD4 CE-Mark

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT(R) CD4 test for helping to manage people living with HIV, following successful performance evaluations in India and the UK.

The successful completion of the CE-Mark process means these tests, which indicate whether a person's CD4 count is higher or lower than 350 cells/mm(3), are available for general sale through business to business channels in countries not requiring individual product registration. The technical file forms the basis of the additional regulatory approval the Company will seek through the World Health Organisation Prequalification programme which assesses in vitro diagnostics tests for priority diseases and their suitability for use in resource-limited settings. A successful completion of this process will enable Omega to become eligible for public sector procurement. The Company anticipates that this process is likely to be completed during the second half of the next financial year.

In addition, the Company is looking to expand its VISITECT(R) product portfolio and is working on an additional version of the VISITECT(R) CD4 test which utilises a 200 cells/ mm(3) cut-off. Recent global health guidelines confirm an opportunity also exists for a test that can indicate advanced HIV disease (a CD4 cell count which is lower than 200 cells/mm(3)) and the Company is working to ensure it has a product portfolio encompassing both existing and new opportunities.

Andrew Shepherd, Chief Executive Officer of Omega, commented: "We are pleased to have achieved this major milestone and whilst the early opportunities are likely to lead to modest sales during the next twelve months, we anticipate generating significant demand once we have completed all the regulatory hurdles. We look forward to providing the global health community with unique point-of-care tests which address a significant unmet need."

Contacts:

 
 Omega Diagnostics Group                             Tel: 01259 763 030 
  PLC 
 Andrew Shepherd, Chief                        www.omegadiagnostics.com 
  Executive 
 Kieron Harbinson, Group 
  Finance Director 
 Jag Grewal, Group Sales 
  and Marketing Director 
 
 finnCap Ltd                                         Tel: 020 7220 0500 
 Geoff Nash/James Thompson 
  (Corporate Finance) 
 Mia Gardner (Corporate 
  Broking) 
 
 Walbrook PR Limited         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                        Mob: 07980 541 893 
 Lianne Cawthorne                                    Mob: 07584 391 303

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESUWVNRBUAAUAA

(END) Dow Jones Newswires

November 29, 2017 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024